Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, Buisson L, Mahéo S, Do Souto Ferreira L, Pavageau L, Hulin C, Marolleau JP, Voillat L, Belhadj K, Divoux M, Slama B, Brechignac S, Macro M, Stoppa AM, Sanhes L, Orsini-Piocelle F, Fontan J, Chretien ML, Demarquette H, Mohty M, Avet-Loiseau H, Corre J. Schavgoulidze A, et al. Among authors: cazaubiel t. Blood. 2023 Mar 16;141(11):1308-1315. doi: 10.1182/blood.2022017863. Blood. 2023. PMID: 36375118 Free PMC article.
Risk and Response-Adapted Treatment in Multiple Myeloma.
Cazaubiel T, Mulas O, Montes L, Schavgoulidze A, Avet-Loiseau H, Corre J, Perrot A. Cazaubiel T, et al. Cancers (Basel). 2020 Nov 24;12(12):3497. doi: 10.3390/cancers12123497. Cancers (Basel). 2020. PMID: 33255368 Free PMC article. Review.
Multiple Myeloma: Heterogeneous in Every Way.
Schavgoulidze A, Cazaubiel T, Perrot A, Avet-Loiseau H, Corre J. Schavgoulidze A, et al. Among authors: cazaubiel t. Cancers (Basel). 2021 Mar 13;13(6):1285. doi: 10.3390/cancers13061285. Cancers (Basel). 2021. PMID: 33805803 Free PMC article. Review.
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
Cazaubiel T, Leleu X, Perrot A, Manier S, Buisson L, Maheo S, Do Souto Ferreira L, Lannes R, Pavageau L, Hulin C, Marolleau JP, Voillat L, Belhadj K, Divoux M, Slama B, Brechignac S, Macro M, Stoppa AM, Sanhes L, Orsini-Piocelle F, Fontan J, Chretien ML, Demarquette H, Mohty M, Schavgoulidze A, Avet-Loiseau H, Corre J. Cazaubiel T, et al. Blood. 2022 Apr 28;139(17):2666-2672. doi: 10.1182/blood.2021014968. Blood. 2022. PMID: 35171994 Free article.
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Schavgoulidze A, Lauwers-Cances V, Perrot A, Cazaubiel T, Chretien ML, Moreau P, Facon T, Leleu X, Karlin L, Stoppa AM, Decaux O, Belhadj K, Arnulf B, Mohty M, Ariette CM, Fohrer-Sonntag C, Lenain P, Marolleau JP, Tiab M, Araujo C, Orsini-Piocelle F, Jaccard A, Roussel M, Benboubker L, Eveillard JR, Dib M, Divoux M, Attal M, Avet-Loiseau H, Corre J. Schavgoulidze A, et al. Among authors: cazaubiel t. Haematologica. 2023 May 1;108(5):1374-1384. doi: 10.3324/haematol.2021.280566. Haematologica. 2023. PMID: 36172814 Free PMC article.
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.
Lannes R, Samur M, Perrot A, Mazzotti C, Divoux M, Cazaubiel T, Leleu X, Schavgoulidze A, Chretien ML, Manier S, Adiko D, Orsini-Piocelle F, Lifermann F, Brechignac S, Gastaud L, Bouscary D, Macro M, Cleynen A, Mohty M, Munshi N, Corre J, Avet-Loiseau H. Lannes R, et al. Among authors: cazaubiel t. J Clin Oncol. 2023 Mar 20;41(9):1695-1702. doi: 10.1200/JCO.21.01987. Epub 2022 Nov 7. J Clin Oncol. 2023. PMID: 36343306 Free PMC article.
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.
Schavgoulidze A, Perrot A, Cazaubiel T, Leleu X, Montes L, Jacquet C, Belhadj K, Brechignac S, Frenzel L, Chalopin T, Rey P, Schiano de Collela JM, Dib M, Caillot D, Macro M, Fontan J, Buisson L, Pavageau L, Roussel M, Manier S, Mohty M, Martinet L, Avet-Loiseau H, Corre J. Schavgoulidze A, et al. Among authors: cazaubiel t. Blood Cancer J. 2023 Oct 26;13(1):160. doi: 10.1038/s41408-023-00933-4. Blood Cancer J. 2023. PMID: 37880285 Free PMC article. No abstract available.
VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
Heraudet L, Galtier J, Favre S, Peyraud F, Cazaubiel T, Leroy H, Mottal N, Gros FX, Forcade E, Clément L, Dumas PY, Pigneux A, Leguay T. Heraudet L, et al. Among authors: cazaubiel t. Br J Haematol. 2022 Aug;198(3):523-527. doi: 10.1111/bjh.18218. Epub 2022 May 7. Br J Haematol. 2022. PMID: 35524489
Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.
Gros FX, Cazaubiel T, Forcade E, Lechevalier N, Leguay T, Servant V, Tabrizi R, Clement L, Dumas PY, Bidet A, Pigneux A, Vigouroux S, Milpied N. Gros FX, et al. Among authors: cazaubiel t. Bone Marrow Transplant. 2017 Jul;52(7):1047-1048. doi: 10.1038/bmt.2017.78. Epub 2017 Jun 5. Bone Marrow Transplant. 2017. PMID: 28581465 No abstract available.
13 results